29-01-2025 15:00
Hearing on 'Overreliance on imports of Active Pharmaceutical Ingredients'

The European Union faces a growing challenge in securing its supply of essential pharmaceuticals, with the majority of its APIs and finished medicines currently imported from Asia. The European Union's increasing dependence on API supplies has led to a partial loss of capability to manufacture active substances independently, which poses a potential threat to public health in the Member States. The public hearing will allow for a discussion on ways to support the production of APIs and finished medicines within Europe.